Form 4: Anika Therapeutics Director Stephen Richard Reports Acquisition and Disposal of Common Stock
SEC Form 4 Filing
Director Stephen Richard reports acquiring and disposing of Anika Therapeutics common stock and restricted stock units.
Summary
- On July 9, 2024, Stephen Richard, a director of Anika Therapeutics, Inc., reported acquiring 5,771 shares of common stock.
- The acquisition was related to restricted stock units (RSUs).
- Each RSU represents a contingent right to receive one share of the company's common stock.
- These RSUs vest in full on the earlier of the 2025 annual meeting of the company's stockholders or July 9, 2025.
- Richard also reported disposing of 33,707 shares of common stock.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing reporting stock transactions by a company director, indicating a neutral sentiment.
Future Outlook
The vesting of the RSUs is contingent upon the earlier of the 2025 annual meeting or July 9, 2025.
Industry Context
This filing is a routine disclosure of stock transactions by a company insider, which is common in the biopharmaceutical industry.
Stakeholder Impact
- The transaction may have a minor impact on shareholders as it reflects insider activity, but the overall effect is likely minimal.
Key Dates
| Date | Description |
|---|---|
| 07/09/2024 | Date of transaction: Acquisition of 5,771 shares and disposal of 33,707 shares. |
| 07/09/2025 | RSUs vest in full on the earlier of the 2025 annual meeting of the Company's stockholders or July 9, 2025. |
| 07/11/2024 | Date of signature of the report. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.